A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Iron Dextran
Saralasin
The risk or severity of hyperkalemia can be increased when Mibefradil is combined with Saralasin.
Iron Dextran
Danaparoid
The risk or severity of hyperkalemia can be increased when Mibefradil is combined with Danaparoid.
Iron Dextran
Sulodexide
The risk or severity of hyperkalemia can be increased when Mibefradil is combined with Sulodexide.
Iron Dextran
Penicillin G Acyl-Serine
The risk or severity of hyperkalemia can be increased when Mibefradil is combined with Penicillin G Acyl-Serine.
Iron Dextran
Saprisartan
The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Mibefradil.
Iron Dextran
Forasartan
The risk or severity of hyperkalemia can be increased when Forasartan is combined with Mibefradil.
Iron Dextran
Enoxaparin
The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Mibefradil.
Iron Dextran
Rescinnamine
The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Mibefradil.
Iron Dextran
Heparin
The risk or severity of hyperkalemia can be increased when Heparin is combined with Mibefradil.
Iron Dextran
Irbesartan
The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Mibefradil.
Iron Dextran
Fingolimod
Mibefradil may increase the bradycardic activities of Fingolimod.
Iron Dextran
Rivastigmine
Rivastigmine may increase the bradycardic activities of Mibefradil.
Iron Dextran
Poractant alfa
Mibefradil may increase the bradycardic activities of Poractant alfa.
Iron Dextran
Lanreotide
Mibefradil may increase the bradycardic activities of Lanreotide.
Iron Dextran
Beractant
Mibefradil may increase the bradycardic activities of Beractant.
Iron Dextran
Calfactant
Mibefradil may increase the bradycardic activities of Calfactant.
Iron Dextran
Lucinactant
Mibefradil may increase the bradycardic activities of Lucinactant.
Iron Dextran
Fostemsavir
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Mibefradil.
Iron Dextran
Ebastine
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Mibefradil.
Iron Dextran
Rilpivirine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Mibefradil.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3